Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rheumatoid arthritis drug study halted early – what we know

NCT ID NCT06031415

Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called GS-0272 in adults with rheumatoid arthritis to see if it is safe and how the body processes it. The trial was stopped early, so results are limited. About 55 people were planned to take part, receiving either the drug or a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

55 people

The number who actually took part.

Started

Sep 2023

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Age limit for the Republic of Korea for male or nonpregnant female is between 19 and 75 years of age. Part A (Rheumatoid Arthritis (RA) Cohorts)-Specific Inclusion Criteria: * Diagnosis of RA at least 3 months prior to screening fulfilling the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria. * Ongoing treatment with 1 or 2 conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for at least 12 weeks prior to the first dose of study drug, with a stable dose for at least 4 weeks prior to the first dose of study drug, as follows: * Individuals must not be on a biologic disease-modifying antirheumatic drugs (bDMARD)/targeted synthetic disease-modifying antirheumatic drug (tsDMARD) at Day 1 or during the study and must discontinue b/tsDMARD use for at least 4 weeks (with the exception of rituximab, which must be discontinued for at least 16 weeks) prior to the first dose of study drug. Part B (Active RA Cohort)-Specific Inclusion Criteria: * Participant is seropositive as demonstrated by a positive anti-cyclic citrullinated peptide (anti-CCP) antibody and/or positive rheumatoid factor at screening. * Participant has an elevated high-sensitivity C-reactive protein (hsCRP) greater than upper limit of normal (ULN). * Participant has 6 or more swollen and 6 or more tender joints as assessed on the SJC66/TJC68. Distal interphalangeal joints will not be counted towards the 6 joint eligibility. * Participant has had inadequate response or intolerance to at least 1 but not more than 3 bDMARD/tsDMARD therapeutics with no more than 2 MOAs. A lack of response is defined as documented continued or recurrent disease activity after at least 12 weeks of treatment of RA. Key Exclusion Criteria: * Meet any of the protocol-specified infection criteria (hepatitis C, Hepatitis B, HIV, tuberculosis, others). * Inadequate response or intolerance to more than 3 bDMARDs/tsDMARDs with more than 2 MOAs. Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis

Contacts and locations

Locations

  • 1238 E. Arrow Hwy

    Upland, California, 91786, United States

  • 1600 Republic Parkway

    Mesquite, Texas, 75150, United States

  • ARENSIA Exploratory Medicine LLC

    Tbilisi, 0112, Georgia

  • Accurate Clinical Research, Inc.

    Houston, Texas, 77089, United States

  • Ajou University Hospital

    Suwon, 16499, South Korea

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania, 16635, United States

  • Arizona Arthritis & Rheumatology Associates P.C.

    Glendale, California, 85306, United States

  • Cambridge Clinical Research Centre, Rheumatology Research Unit - E6, Addenbrookes Hospital

    Cambridge, CB2 0QQ, United Kingdom

  • Chungnam National University Hospital

    Daejeon, 35015, South Korea

  • Clinical Research of West Florida, Inc.

    Clearwater, Florida, 33765, United States

  • Greater Chicago Specialty Physicians/ Clinical Investigation Specialists

    Niles, Illinois, 60714, United States

  • Greater Chicago Specialty Physicians/Clinical Investigation Specialists, Inc.

    Schaumburg, Illinois, 60195, United States

  • IMSP Republican Clinical Hospital "Timofei Mosneaga", ARENSIA E.M.

    Chisinau, MD-2025, Moldova

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida, 32216, United States

  • Kings College Hospital

    London, SE5 9RS, United Kingdom

  • NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust

    Southampton, SO16 6YD, United Kingdom

  • PA Regional Center for Arthritis and Osteoporosis Research

    Wyomissing, Pennsylvania, 19610, United States

  • Precision Comprehensive Clinical Research Solutions

    Colleyville, Texas, 76034, United States

  • Precision Comprehensive Clinical Research Solutions

    Irving, Texas, 75061, United States

  • Seoul National University Hospital

    Seoul, 110 744, South Korea

  • Simbec Research Limited

    Merthyr Tydfil, CF48 4DR, United Kingdom

  • Stanford School of Medicine, Division of Immunology & Rheumatology

    Palo Alto, California, 94304, United States

  • Summit Headlands LLC

    Portland, Oregon, 97210, United States

  • University Hospitals Coventry & Warwickshire NHS Trust

    Coventry, CV2 2DX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.